Lantox—The Chinese Botulinum Toxin Drug—Complete English Bibliography and Comprehensive Formalised Literature Review

Toxins, 2021 · DOI: 10.3390/toxins13060370 · Published: May 22, 2021

Simple Explanation

This review focuses on lanbotulinumtoxinA (LAN), a botulinum toxin type A drug introduced in China in 1997 and now available in various regions under different brand names. The literature on LAN is mostly in Chinese, which limits its accessibility to the international community. This paper aims to provide a complete English bibliography of LAN publications and a comprehensive literature review. The review covers a wide range of indications for LAN, including motor disorders (e.g., dystonia, hemifacial spasm), glandular conditions (e.g., hyperhidrosis), pain management (e.g., migraine), and aesthetic applications (e.g., wrinkle treatment). The analysis includes various study types such as randomized controlled trials, interventional studies, and observational studies. The findings suggest that LAN has a similar efficacy and safety profile compared to other botulinum toxin type A drugs, particularly onabotulinumtoxinA (Botox), when used with a 1:1 conversion ratio. However, the authors emphasize the need for large, controlled, multicenter studies to support LAN's registration in Europe and North America.

Study Duration

More than 20 years

Participants

379 LAN publications (322 in Chinese and 57 in English)

Evidence Level

Reviews, guidelines, randomised controlled trials, interventional studies, observational studies, case studies

Key Findings

1
A total of 379 LAN publications were identified, with the majority published in Chinese. The review categorizes these publications based on indications, including motor, glandular, pain, and aesthetic uses.
2
LAN has been used for over 20 years, making it one of the longest-used botulinum toxin drugs globally. It is applied across various medical specialties, including neurology, aesthetics, pediatrics, ophthalmology, and urology.
3
LAN demonstrates similar efficacy and safety profiles compared to other botulinum toxin type A drugs, particularly onabotulinumtoxinA, when converted at a 1:1 ratio. Biological potency studies support this equipotency.

Research Summary

This review provides a comprehensive overview of lanbotulinumtoxinA (LAN) research, compiling a complete English bibliography and analyzing publications until July 1, 2018. The study categorizes LAN applications across various medical fields, including motor, glandular, pain, and aesthetic indications. The analysis reveals that LAN has been in use for over two decades, with a substantial number of publications covering its efficacy and safety. These publications include randomized controlled trials, interventional studies, observational studies, and case studies. Findings suggest that LAN exhibits similar efficacy and safety characteristics compared to other botulinum toxin type A drugs, specifically onabotulinumtoxinA. However, the authors highlight the necessity for further large-scale, multicenter studies to facilitate LAN's regulatory approval in Europe and North America.

Practical Implications

Clinical Practice

Provides a comprehensive English resource for clinicians interested in using lanbotulinumtoxinA, especially those who may not have access to Chinese language publications.

Regulatory Approval

Highlights the need for large, controlled, multicenter studies to support the registration of lanbotulinumtoxinA in Europe and North America.

Research Direction

Suggests future research should focus on detailed product characteristics, biological potency, production consistency, and stability of lanbotulinumtoxinA.

Study Limitations

1
The review is limited to publications available until July 1, 2018.
2
Publication languages other than English and Chinese were not retrieved.
3
The review acknowledges a relatively low percentage of randomized controlled trials and interventional studies compared to observational and case studies.

Your Feedback

Was this summary helpful?

Back to Pharmacology